At Zencogen, we are committed to advancing biotechnology for a healthier future. We utilize humanized, and highly specific antibodies to target cancers that are refractory, and also to address unmet clinical needs.
Our Founder and CEO is Dr. Xinmin Zheng.
Dr. Zheng and et al were first to demonstrate that PTPRA could activate endogenous Src family kinases, and that this induced cell transformation and tumourgenesis.
Thus, PTPRA was the first tyrosine phosphatase to be classified as a proto-oncoprotein.
Dr. Zheng also observed that PTPRA protein is overexpressed in certain human cancers, suggesting PTPRA should be considered a specific target for the advancement of next generation targeted therapies.